Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer

Authors

Xuxu Gou, Baylor College of Medicine
Shunqiang Li, Washington University School of Medicine in St. Louis
et al.

Journal

Cancer Research

Publication Date

12-15-2021

Volume

81

Issue

24

First Page

6259

Last Page

6272

Document Type

Open Access Publication

DOI

10.1158/0008-5472.CAN-21-1256

Rights and Permissions

Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

Recommended Citation

Gou, Xuxu; Li, Shunqiang; and et al., "Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer." Cancer Research. 81, 24. 6259 - 6272. (2021).
https://digitalcommons.wustl.edu/oa_4/3665

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.